Janet K. Yamamoto
Department of Infectious Diseases & Immunology
PO Box 110880
2015 SW 16th Ave
Gainesville, FL 32608-0880
FAX: (352) 392-9704
PhD, Microbiology (Immunology), The University of Texas Medical Branch, Galveston, 1981
Honors and Awards
- Florida Inventors Hall of Fame, 2015.
- National Academy of Inventors (NIA) Fellow, 2014.
- University of Florida Research Foundation Professorshoip Award, 2011
- Faculty Achievement Recognition, University of Florida, 2007
- Ad hoc grant reviewer, Medical Research Council, UK, 2006
- Regular member, AIDS Immunology & Pathogenesis Study Section, NIH, NIAID, 2005-present
- Pfizer Animal Health Award for Research Excellence, University of Florida, 2005
- Ad hoc grant reviewer, Medical Research Council, UK, 2003, 2004
- Honorary member, Upsilon Chapter of the Society of Phi Zeta, 2002
- University of Florida Research Foundation Professorshoip Award, 2002
- Ad hoc member, Study Section on AIDS K08, NIH, 2002
- International Advisory Committee, Intl. Feline Retrovirus Research Symposium, 2000-present
- Ad hoc member, AIDS ARR 2 Study Section, NIH, 2000, 2004
- Ad hoc member, Vaccine Special Emphasis Panel (VACC 01, 02, 03, 010), NIH, 1998-2005
- Ad hoc member, Study Section on Small Business and STTR Grants, NIH, NIMH, 1998
- Ad hoc team leader, Primate Research Center Site Visit, NIH, NCRR, 1998
- Pfizer Animal Health Award for Research Excellence, University of Florida, 1996
- Ad hoc member, Primate Research Center Site Visit, NIH, NCRR, 1996
- Ad hoc member, Minority Enhancement Program Study Section, NIH, NIAID, 1995
- Ad hoc member, Panel on RFA on Blood Brain Barrier in HIV, NIH, NIMH, 1995
- Regular member, AIDS & Immunology Study Section (MHAI2), NIH, NIHM, 1994-1998
- Member, Immunology & Microbiology Study Section, American Heart Assoc., 1993-1995
Research Accomplishments and Current Interests
Dr. Yamamoto has been working in the HIV-1 field since 1984 and is the co-discoverer of feline immunodeficiency virus (FIV, feline counterpart of HIV) and the inventor of the first commercial FIV vaccine (Fel-O-Vax® FIV, sold by Pfizer and Boehringer). Under the leadership of Dr. Murray Gardner (director of CFAR) in 1984, she set up the first HIV-1 laboratory at the University of California, Davis (UCD) which later became the main laboratory of the NIH-funded Center for AIDS Research (CFAR) at UCD. She is the first to publish together with Drs. Francois Barré-Sinousi (Nobelauriate) and Gardner that IFNα and IFNβ suppresses HIV-1 replication but IFNγ enhances HIV-1 replication. Based on her experience in large-scale production of HIV-1 viruses and HIV-1 immunoblots, she also served as the consultant on the second FDA-approved HIV-1 immunoblot by Bio-Rad Laboratories. She has extensive experience in adjuvants for protein vaccines including cytokine (IL12, IL15, IL18, IFNγ) supplement of adjuvants in cats. After the discovery of FIV, her laboratory has focused on the development of FIV vaccine for both prophylaxis and therapeutic uses and FIV infection of cats as the natural small animal model of HIV/AIDS. Her laboratory has been studying the immune mechanism(s) of the protection conferred by prototype and commercial dual-subtype FIV vaccines as an animal model for developing HIV-1 vaccine. Her laboratory has discovered that vaccine-induced T-cell immunity may be more important in prophylactic protection against both homologous-subtype and heterologous-subtype FIV than vaccine-induce antibody immunity. Based on this finding, her laboratory is developing a second-generation FIV vaccine which has no conflict with commercial FIV diagnostics. Her laboratory is also working on identifying T-cell epitopes on HIV for an effective HIV vaccine. Yamamoto has had NIH grant for 30 years and the majority of 85 journal/book publications and 34 patent publications are on FIV or HIV-1.
Recent Publications Related to Current Research Interests
- Aranyos AM, Roff SR, Pu R, Owen JL, Coleman JK, Yamamoto JK. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection. Vaccine 32:1480-1488, 2016. doi: 10.1016/j.vaccine.2016.01.017 2016.
- Roff SR, Sanou MP, Rathore MH, Levy JA, Yamamoto JK. Conserved epitopes on HIV-1, SIV, and FIV p24 proteins are recognized by HIV-1 infected subjects. Hum Vaccin Immunother. 11(6):1540-56, 2015. doi: 10.1080/21645515.2015.1026500. PubMed PMID: 25844718; PubMed Central PMCID: PMC4514358.
- Coleman JK, Pu P, Martin MM, Noon-Song EN, Zwijnenberg R, Yamamoto JK. Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies. Vaccine 32(6):746-54, 2014. doi: 10.1016/j.vaccine.2013.05.024. PubMed PMID: 23800540; PubMed Central PMCID: PMC4304674.
- Roff SR, Noon-Song EN, Yamamoto JK. The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol. 4:498, Jan 13, 2014; doi: 10.3389/fimmu.2013.00498. Review. PubMed PMID: 24454311; PubMed Central PMCID: PMC3888948.
- Sanou MP, Roff S, Mennella A, Sleasman JW, Rathore MH, Yamamoto JK*, Levy JA. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol. 87(18):10004-15, 2013; doi: 10.1128/JVI.00359-13. PubMed PMID: 23824804; PubMed Central PMCID: PMC3754003 (*Corresponding author).
Complete List of Published Work in My NCBI Collection, including 34 patent issued and pending, can be found here.
Additional publications here.